Search Results
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for NDMM
ASCO2022: Lenalidomide, bortezomib, and dexamethasone (RVd) ± ASCT & R maintenance to progressio...
Dr. Paul G. Richardson Provides Study Updates on the Phase 3 DETERMINATION Trial for NDMM patients
WBMT Webinar: Stem cell transplantation for multiple myeloma: a global perspective
How do we decide if maintenance is going to be a fixed or continuous duration?
Current and Future Treatment of Multiple Myeloma
Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-Farber
Integrated Myeloma Management for Transplant-Eligible Patients
COMy Online 2020 - Session 8 & 9
Approaches To Achieve the Best Possible Outcomes in Myeloma
Upfront Therapy for the ASCT-Eligible Patient: (pt. 3 of 5 - IMF ASH Satellite)
What is the best induction for transplant-eligible myeloma patients?
